Nalaganje...
Rituximab efficiently depletes increased CD20 expressing T cells in multiple sclerosis patients()
In multiple sclerosis (MS()) B cell depleting therapy using monoclonal anti-CD20 antibodies, including rituximab (RTX) and ocrelizumab (OCR), effectively reduces disease activity. Based on indirect evidence, it is generally believed that elimination of the antigen presenting capabilities and antigen...
Shranjeno v:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2014
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4082756/ https://ncbi.nlm.nih.gov/pubmed/24928997 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1400118 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|